Andra AP fonden Acquires New Position in Moderna, Inc. (NASDAQ:MRNA)

Andra AP fonden bought a new position in Moderna, Inc. (NASDAQ:MRNA) in the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 2,300 shares of the company’s stock, valued at approximately $273,000.

Other institutional investors also recently bought and sold shares of the company. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Moderna in the second quarter valued at $26,000. Ogorek Anthony Joseph NY ADV acquired a new stake in Moderna in the 4th quarter worth about $27,000. Cedar Wealth Management LLC grew its holdings in Moderna by 45.0% in the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after buying an additional 90 shares during the period. Westside Investment Management Inc. acquired a new position in shares of Moderna during the 1st quarter valued at about $32,000. Finally, Family Firm Inc. acquired a new stake in shares of Moderna in the second quarter worth approximately $33,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Trading Down 12.4 %

MRNA opened at $69.68 on Friday. Moderna, Inc. has a 12-month low of $62.55 and a 12-month high of $170.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92. The stock has a market capitalization of $26.78 billion, a PE ratio of -4.45 and a beta of 1.68. The firm’s fifty day moving average price is $96.06 and its 200 day moving average price is $111.86.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. The business had revenue of $241.00 million for the quarter, compared to analyst estimates of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The company’s revenue for the quarter was down 29.9% on a year-over-year basis. During the same quarter in the prior year, the business posted ($3.62) EPS. As a group, research analysts expect that Moderna, Inc. will post -9.52 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on MRNA. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research note on Thursday, June 27th. Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a “sell” rating to a “hold” rating and cut their price target for the company from $85.00 to $80.00 in a report on Wednesday, August 7th. Royal Bank of Canada downgraded shares of Moderna from an “outperform” rating to a “sector perform” rating and cut their target price for the company from $125.00 to $90.00 in a research note on Monday, August 5th. Piper Sandler reaffirmed an “overweight” rating and issued a $157.00 target price (down previously from $214.00) on shares of Moderna in a research report on Friday, August 2nd. Finally, Hsbc Global Res upgraded Moderna from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 28th. Ten equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Moderna currently has an average rating of “Hold” and a consensus target price of $123.79.

Insiders Place Their Bets

In related news, President Stephen Hoge sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $138.16, for a total transaction of $2,072,400.00. Following the sale, the president now directly owns 1,457,089 shares of the company’s stock, valued at approximately $201,311,416.24. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, CFO James M. Mock sold 689 shares of the business’s stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $118.24, for a total transaction of $81,467.36. Following the completion of the sale, the chief financial officer now owns 7,269 shares of the company’s stock, valued at approximately $859,486.56. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, President Stephen Hoge sold 15,000 shares of the stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $138.16, for a total transaction of $2,072,400.00. Following the sale, the president now owns 1,457,089 shares in the company, valued at approximately $201,311,416.24. The disclosure for this sale can be found here. Insiders have sold a total of 108,158 shares of company stock valued at $13,239,712 in the last quarter. Insiders own 15.70% of the company’s stock.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.